TY - JOUR
T1 - Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)
AU - Nishio, Makoto
AU - Sugawara, Shunichi
AU - Atagi, Shinji
AU - Akamatsu, Hiroaki
AU - Sakai, Hiroshi
AU - Okamoto, Isamu
AU - Takayama, Koichi
AU - Hayashi, Hidetoshi
AU - Nakagawa, Yuki
AU - Kawakami, Tomohisa
N1 - Funding Information:
The authors thank the patients, their families, and the clinical study site investigators and staff for their contributions to the study. This study was supported by F. Hoffmann-La Roche Ltd . Medical writing assistance for this manuscript was provided by Jonathan Lee, PhD, of Health Interactions, and funded by Chugai Pharmaceutical Co, Ltd. F. Hoffmann-La Roche Ltd /Genentech, Inc. sponsored the study, provided study drugs, was involved in the study design, data collection, data analysis, and data interpretation for the IMpower133 primary analysis, and gave approval to submit for this publication. Chugai Pharmaceutical Co, Ltd was involved in the data collection for the IMpower133 primary analysis, data analysis, data interpretation, and writing of the report for the Japanese subgroup analysis of IMpower133 and gave approval to submit for publication. Makoto Nishio had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Funding Information:
Dr Nishio reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and grants and personal fees from Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, Chugai Pharmaceutical Co, Ltd, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, and Novartis; personal fees from Boehringer Ingelheim and Sankyo Healthcare; and grants from Astellas outside the submitted work. Dr Sugawara reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and lecture fees from Chugai Pharmaceutical Co, Ltd, MSD, AstraZeneca, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, Novartis, Eli Lilly, Taiho Pharmaceutical, and Kyowa Hakko Kirin outside the submitted work. Dr Atagi reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and grant and personal fees from MSD, Boehringer Ingelheim, Chugai Pharmaceutical Co, Ltd, AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, Pfizer and Bristol-Myers Squibb; and personal fees from Hisamitsu outside the submitted work. Dr Akamatsu reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and grants and personal fees from MSD K.K. and lecture fees from Chugai Pharmaceutical Co, Ltd, Bristol-Myers Squibb, and AstraZeneca outside the submitted work. Dr Sakai reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and personal fees from Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical Co, Ltd, Eli Lilly, and MSD outside of the submitted work. Dr Okamoto reports grant support from Boehringer Ingelheim and grant and nonfinancial support from F. Hoffman-La Roche Ltd during the conduct of this study and grant and personal fees from AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD Oncology, Eli Lilly, Bristol-Myers Squibb, and Chugai Pharmaceutical Co, Ltd; grants from Astellas Pharma, Novartis, and AbbVie; and personal fees from Pfizer outside the supported work. Dr Takayama reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and lecture fees from Chugai Pharmaceutical Co, Ltd outside the submitted work. Dr Hayashi reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and grants and personal fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc, and Ono Pharmaceutical Co, Ltd, and personal fees from Bristol-Myers Squibb, Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc, and Taiho Pharmaceutical outside the submitted work. Mr Nakagawa reports grant and nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of this study and is an employee of Chugai Pharmaceutical Co, Ltd with stock ownership. Dr Kawamaki reports nonfinancial support from F. Hoffmann-La Roche Ltd and Chugai Pharmaceutical Co, Ltd during the conduct of the study and is an employee of Chugai Pharmaceutical Co, Ltd.The authors thank the patients, their families, and the clinical study site investigators and staff for their contributions to the study. This study was supported by F. Hoffmann-La Roche Ltd. Medical writing assistance for this manuscript was provided by Jonathan Lee, PhD, of Health Interactions, and funded by Chugai Pharmaceutical Co, Ltd. F. Hoffmann-La Roche Ltd/Genentech, Inc. sponsored the study, provided study drugs, was involved in the study design, data collection, data analysis, and data interpretation for the IMpower133 primary analysis, and gave approval to submit for this publication. Chugai Pharmaceutical Co, Ltd was involved in the data collection for the IMpower133 primary analysis, data analysis, data interpretation, and writing of the report for the Japanese subgroup analysis of IMpower133 and gave approval to submit for publication. Makoto Nishio had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/11
Y1 - 2019/11
N2 - Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.
AB - Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.
UR - http://www.scopus.com/inward/record.url?scp=85071137609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071137609&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2019.07.005
DO - 10.1016/j.cllc.2019.07.005
M3 - Article
C2 - 31466854
AN - SCOPUS:85071137609
SN - 1525-7304
VL - 20
SP - 469-476.e1
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 6
ER -
